Obesity is a key therapeutic area for Pfizer, with danuglipron showing potential as a competitive oral GLP-1 molecule. The preferred once-daily formulation aims to address medical needs of people with obesity.
With dose optimization studies planned for the second half of 2024, Pfizer intends to evaluate multiple doses of danuglipron to inform registration-enabling studies. The goal is to advance a competitive oral GLP-1 molecule.
Collection
[
|
...
]